by Gastric motility disorder refers to a condition where there is a problem in the muscular contractions of the stomach that hampers the forward movement of food and churning motion. Gastric motility disorder drugs help stimulate gastric emptying by modulating transit through the stomach and small intestine. The global gastric motility disorder drug market is gaining traction due to the increasing prevalence of gastrointestinal disorders and growing geriatric population susceptible to gastric motility issues. The market is estimated to be valued at US$ 57.65 Bn in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the gastric motility disorder drug market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals.
The key opportunities in the market include developing novel drug formulations with fewer side effects and higher efficacy. Selective gastrokinetic agents targeting specific motility receptors like the 5-HT4 receptor hold significant potential.
Advances in the understanding of gastric physiology at the molecular level have led to the development of selective gastroprokinetic drugs modulating gastric motility through specific pathways like dopamine D2 receptor antagonists and motilin receptor agonists with improved safety profiles over existing medications.
Market Drivers
The increasing geriatric population is one of the key drivers for the gastric motility disorder drug market. Older adults have a higher risk of developing gastric motility issues due to age-related changes in gastrointestinal function. Moreover, the rising prevalence of diabetes and obesity, which are risk factors for gastric motility disorders, is also contributing to the growth of this market.
Challenges in Gastric Motility Disorder Drug Market
Gastric Motility Disorder Drug Market size is facing various challenges which are restraining its growth. Diagnosis of gastric motility disorders poses difficulty due to lack of clear clinical symptoms. Conditions such as gastroparesis are still often misdiagnosed. Lack of disease awareness among patients as well as physicians further adds to the challenge of early diagnosis. There is absence of standardized diagnostic tests and criteria for defining the severity of disease. This leads to inconsistent and delayed diagnosis. Moreover, the pathophysiology of gastric motility disorders remains unclear. This limits development of novel and targeted treatment options. Significant drug safety issues also exist with the currently available therapies which have side effects like hypersensitivity reactions. Overall high treatment costs associated with gastric motility drugs is another impediment for patients in developing countries.
SWOT Analysis
Strength: Presence of large patient pool suffering from gastric motility disorders worldwide. Strong pipeline of drugs in clinical trials offering improved safety and efficacy.
Weakness: Unclear disease understanding and lack of standardized diagnosis. Significant side effects of existing drug therapies.
Opportunity: Growing disease awareness programs by patient advocacy groups and manufacturers. Development of newer treatment modalities like neurostimulation and surgical procedures.
Threats: Safety issues continue to affect drug development. Entry of generic competition eroding sales of branded drugs.
Geographical Regions
Gastric Motility Disorder Drug Market Regional Analysis North America currently dominates the gastric motility disorder drug market, accounting for over 40% market share in terms of value. High disease prevalence, developed healthcare infrastructure, and favorable reimbursement policies drive high drug consumption in the US and Canada. Asia Pacific is expected to be the fastest growing regional market during the forecast period. This is attributed to rising geriatric population, increasing incidence of gastroparesis due to diabetes, and improved access to healthcare in countries such as India and China.
The gastric motility disorder drug market is most concentrated in developed countries of Western Europe. Countries like Germany, UK, France and Italy collectively generate more than one third of global revenues. However, market growth is slowing down in these mature markets due to generic competition and strict cost containment measures. Latin America and Middle East & Africa offer emerging opportunities for manufacturers, aided by growing medical tourism in these regions.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
